{
    "clinical_study": {
        "@rank": "144419", 
        "arm_group": [
            {
                "arm_group_label": "AI plus Dimethyldiguanide", 
                "arm_group_type": "Experimental", 
                "description": "AI 1 tablet qd plus Dimethyldiguanide 0.5 bid"
            }, 
            {
                "arm_group_label": "Aromatase Inhibitor", 
                "arm_group_type": "Active Comparator", 
                "description": "AI monotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic\n      breast cancer."
        }, 
        "brief_title": "Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The addition of dimethyldiguanide might increase the efficacy of AI in patients with\n      metastatic breast cancer after the failure of the first line endocrine therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  postmenopausal HR positive breast cancer patients;\n\n          -  inoperable locally advanced or metastatic breast cancer patients;\n\n          -  candidate for endocrine therapy;\n\n          -  ECOG equal to or less than 1;\n\n          -  adequate bone marrow function(Hb>=90g/L, WBC >=3.5\u00d710^9/L,ANC>=1.5\u00d710^9/L,\n             PLT>=80\u00d710^9/L; adequate renal function(Ccr<=ULN);adequate liver\n             function(ALT,AST,AKP<=2.5*ULN,or <=5*ULN if liver metastases)\n\n          -  life expectancy >=12weeks;\n\n          -  no severe history disease of liver,heart,lung or kidney;\n\n          -  written informed consent form;\n\n        Exclusion Criteria:\n\n          -  Her-2 overexpression;\n\n          -  patients who has visceral endocrisis\uff1b"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654185", 
            "org_study_id": "Fudan BR2012-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "AI plus Dimethyldiguanide", 
                "description": "AI 1 tablet per day Dimethyldiguanide 0.5 bid", 
                "intervention_name": "AI plus Dimethyldiguanide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "letrozole or exemestane", 
                    "Dimethyldiguanide"
                ]
            }, 
            {
                "arm_group_label": "Aromatase Inhibitor", 
                "description": "1 tablet per day", 
                "intervention_name": "Aromatase Inhibitor", 
                "intervention_type": "Drug", 
                "other_name": "letrozole or exemestane"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Exemestane", 
                "Letrozole", 
                "Aromatase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "huxicun@gmail.com", 
                "last_name": "Xichun Hu, MD,PhD", 
                "phone": "64175590", 
                "phone_ext": "5006"
            }, 
            "contact_backup": {
                "email": "wangbiyun@msn.com", 
                "last_name": "Biyun Wang, MD", 
                "phone": "64175590", 
                "phone_ext": "5000"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Dimethyldiguanide Combined With AI Compared to AI in Postmenopausal HR(+) Metastatic Breast Cancer.", 
        "overall_contact": {
            "email": "huxicun@gmail.com", 
            "last_name": "Xichun Hu, MD, PhD", 
            "phone": "64175590", 
            "phone_ext": "5006"
        }, 
        "overall_contact_backup": {
            "email": "wangbiyun@msn.com", 
            "last_name": "Biyun Wang, MD", 
            "phone": "64175590", 
            "phone_ext": "5000"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Xichun Hu, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression free survival", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654185"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Xichun Hu", 
            "investigator_title": "Deputy director of department of medical oncology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xichun Hu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}